Replies to post #62515 on ViaDerma Inc (VDRM)

[whatarush12]

Dual Carrier Technology is KEY and what differentiates VitaStem from ALL other products on the market!

[0041] The First Aid antibiotic ointment in this embodiment comprises 3% Tetracycline Hydrochloride delivered by Dual Carrier Technology (DCT). DCT is a tissue penetration technology that creates releasable binds to the active to pharmaceutical ingredient, as the carrier transports the drug in a high penetration format through the pathogen cell wall to effectively kill the bacteria and reduce the water activity level (e.g. dehydrate) in the bacteria, for both a pharmaceutical and mechanical kill.

$VDRM

[tomi187]

Patent pending only offers legal protection if and when the patent is granted. If the patent is never granted which at this point it is not it offers no protection at all. The potential protection that it can offer is that the date of the original patent request would come into play in the event of a lawsuit. Again this is only relevant if and when the said patent would be granted. At this point we have been pending for more than 5 yrs. The chance of the patent ever being granted at this point are slim to none.